GlassScriptPhysician profile
Aaron James Pugh
NPI 1427245018
$22,027.78
in general payments reported to CMS, 2019-2025
36 companies · $2,389 in 2025
The $2,389 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,529 · 2020: $340 · 2021: $1,265 · 2022: $1,251 · 2023: $2,796 · 2024: $12K · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,800 · Food and Beverage: $6,727 · Travel and Lodging: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,800.00 |
| Food and Beverage | $6,726.76 |
| Travel and Lodging | $1,116.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,388.69 | 2021-2024 | Interstim |
| Abbvie INC. | $3,027.09 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $943.26 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $876.64 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $873.57 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $653.36 | 2019-2025 | Livdelzi |
| Celgene Corporation | $558.36 | 2021-2024 | Zeposia |
| Pfizer INC. | $443.47 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $372.41 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $311.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $279.74 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $238.49 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $208.05 | 2019-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $158.47 | 2021-2024 | Stelara |
| Ardelyx, INC. | $154.39 | 2023-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $140.43 | 2021 | |
| Qol Medical, LLC | $134.78 | 2023-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $131.26 | 2023-2025 | Watchman Access System, Watchman Flx |
| Phathom Pharmaceuticals, INC. | $116.92 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $107.96 | 2019-2024 | Dificid |
| Organon LLC | $101.89 | 2023-2025 | Hadlima, Renflexis |
| Daiichi Sankyo INC. | $99.49 | 2019-2022 | |
| Amgen INC. | $93.75 | 2023 | Avsola, Amjevita |
| Allergan, INC. | $89.95 | 2019 | |
| Shionogi INC | $63.88 | 2019 | |
| Ferring Pharmaceuticals INC. | $60.92 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $58.77 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $56.15 | 2019-2024 | Suflave |
| Medtronic USA, INC. | $53.21 | 2019 | |
| Covidien LP | $48.31 | 2019 | |
| Shire North American Group INC | $43.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $35.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $34.18 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $31.47 | 2024 | |
| Steris Corporation | $18.48 | 2019 | |
| Novo Nordisk INC | $18.37 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Pugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.